Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Meeting Calendar
  3. Past Meetings
  4. ESMO Congress 2024
  5. Satellite Symposia Webcasts

Novartis - The Evolution of HR+/HER2− Early Breast Cancer Clinical Practice: Broadening the Impact of CDK4/6 Inhibitors

Looking Forward: Chemotherapy De-Escalation and Sparing Trials, Closing and Q&A

Date

15 Sep 2024

Session

Novartis - The Evolution of HR+/HER2− Early Breast Cancer Clinical Practice: Broadening the Impact of CDK4/6 Inhibitors

Topics

Tumour Site

Breast Cancer

Presenters

César A. Rodríguez, Peter A. Fasching, Sara Tolaney

Authors

C.A. Rodríguez1, P.A. Fasching2, S.M. Tolaney3

Author affiliations

  • 1 Medical Oncology, University Hospital of Salamanca, 37007 - Salamanca/ES
  • 2 Gynecology And Obstetrics Department, University Hospital Erlangen, 91054 - Erlangen/DE
  • 3 Dana Farber Cancer Institute, 02215 - Boston/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and Introduction

Presenter: César A. Rodríguez

Session: Novartis - The Evolution of HR+/HER2− Early Breast Cancer Clinical Practice: Broadening the Impact of CDK4/6 Inhibitors

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.